Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731177 | 0.88 | KMT2A (0.47) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 | |
| SCHEMBL12731196 | 0.85 | NPC1 (0.51) | MAPTKDM4EPOLBMAPK1TP53 | |
| SCHEMBL5961764 | 0.84 | MAPT (0.45) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 | |
| SCHEMBL12731216 | 0.82 | MAPT (0.44) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 | |
| SCHEMBL5961866 | 0.82 | NPC1 (0.47) | MAPTPOLBTP53SMN1; SMN2KMT2A | |
| SCHEMBL5961869 | 0.81 | MAPT (0.39) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 | |
| SCHEMBL5961768 | 0.81 | LMNA (0.42) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 | |
| SCHEMBL14507438 | 0.80 | MAPT (0.50) | MAPTKDM4EPOLBMAPK1TP53 | |
| SCHEMBL5961772 | 0.77 | MAPT (0.38) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 | |
| SCHEMBL12567530 | 0.77 | TDP1 (0.42) | MAPTKDM4EPOLBMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168734-B2 | Lateral alpha-substituted acrylate compound and polymer thereof | JNC CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | CHISSO CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | LEF1, AFF1, CNKSR1 | MAPT 3921/4885KDM4E 2839/4885POLB 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.